Predictors of early mortality in systemic sclerosis: A case-control study comparing early versus late mortality in systemic sclerosis

Rheumatology International

Volumn 32, Issue 12, 2012, Pages 3841-3844

  Derk, Chris T ^a   Huaman, Gonzalo ^b   Littlejohn, Jayne ^b   Otieno, Franklin ^b   Jimenez, Sergio ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Death; Fibrosis; Mortality; Poor prognosis; Scleroderma; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CENTROMERE ANTIBODY; CYCLOPHOSPHAMIDE; METHOTREXATE; PENICILLAMINE;

ARTICLE; CASE CONTROL STUDY; DISEASE SEVERITY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART; HUMAN; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MEDGESTER SEVERITY SCORE; MEDICAL RECORD REVIEW; MORTALITY; MUSCLE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84872266742     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2301-4     Document Type: Article

References (20)

1. Bryan C, Howard Y, Brennan P, Black C, Silman A (1996) Survival following the onset of scleroderma: Results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 35:1122-1126
2. Bu-Shakra M, Lee P (1995) Mortality in systemic sclerosis: A comparison with the general population. J Rheumatol 22:2100-2102
3. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48:2246-2255
4. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr (2011) Skin thickness progression rate: A predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 70(1):104-109
5. Shervin A, Del Junco D, Sutter K et al (2009) Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 61:1403-1411
6. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:940-944
7. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A et al (2005) Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med 118:2-10
8. Simeon CP, Armadans L, Fonollosa V et al (2003) Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 42:71-75
9. Ferri C, Valentini G, Cozzi F et al (2002) Demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 81:139-153
10. Jacobsen S, Ullman S, Shen GQ et al (2001) Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 28:2454-2459
11. Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437-2444
12. Bryan C, Knight C, Black CM, Silman AJ (1999) Prediction of five-year survival following presentation with scleroderma. Arthritis Rheum 42:2660-2665
13. Bulpitt KJ, Clements PJ, Lachenbruch PA et al (1993) Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma. Ann Intal Med 118:602-609
14. Altman RD, Medsger TA Jr, Block DA, Michel BA (1991) Predictors of survival in systemic sclerosis. Arthritis Rheum 34:403-413
15. Medsger TA Jr (2000) Assessment of damage and activity in systemic sclerosis. Curr Opin Rheum 12:545-548
16. Kuwana M, Kaburaki J, Okano Y et al (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75-83
17. Mittoo S, Wigley FM, Wise RA et al (2011) Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. Open Rheumatol J 5:1-6
18. Bussone G, Mouthon L (2011) Interstitial lung disease in systemic sclerosis. Autoimmun Rev 10:248-255
19. York RI, Farber HW (2011) Pulmonary hypertension screening and evaluation in scleroderma. Curr Opin Rheumatol 23(6):536-544
20. Nikpour M, Stevens WM, Herrick AL et al (2010) Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol 24(6):857-869